[Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica].
8 patients with confirmed psoriatic arthritis were treated with splenopentin for 12 months. A relief of joint pain could be detected under this treatment both after 6 weeks (improvement of the Ritchie-indices: 44%) and after 12 months (improvement: 28%). In contrast to this, X-ray investigations show a worsening of the disease after 12 months. Therefore we conclude that splenopentin alone is not a sufficient therapeutic drug in patients suffering from psoriatic arthritis.
Greiner
J
J
Klinik und Poliklinik für Hautkrankheiten, Humboldt-Universität zu Berlin, DDR.
Miehe
M
M
Weber
H
H
Stoimenov
A
A
Sönnichsen
N
N
Diezel
W
W
D000328:Adult; D015535:Arthritis, Psoriatic / Q000628:therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D013946:Thymopoietins / Q000008:administration & dosage*; D013951:Thymus Hormones / Q000008:administration & dosage*
D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; C060485:berlopentin
Therapeutische Anwendung von Splenopentin (DA SP-5) bei Patienten mit Psoriasis arthropathica.